Los Angeles Capital Management
TRVI icon

Los Angeles Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Los Angeles Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.62K Buy
555
+468
+538% +$5.24K ﹤0.01% 2049
2025
Q4 		$972 Buy
+87
New +$1K ﹤0.01% 2479
2025
Q3 		– Sell
-16,379
Closed -$89.6K – 1535
2025
Q2 		$89.6K Buy
+16,379
New +$102K ﹤0.01% 1261

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Los Angeles Capital Management's TRVI Position: Q1 2026 in Review

Los Angeles Capital Management increased its Trevi Therapeutics (TRVI) stake by 538% in Q1 2026, buying an estimated $5.24K and bringing the position to 555 shares worth $6.62K. The position accounts for ﹤0.01% of the portfolio, ranked #2049.

Los Angeles Capital Management first reported a position in TRVI in Q2 2025 and has held it in 3 quarters since. The position peaked at $89.6K in Q2 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Los Angeles Capital Management held 555 shares of Trevi Therapeutics worth $6.62K as of Q1 2026.
  • Los Angeles Capital Management bought 468 Trevi Therapeutics shares in Q1 2026, an estimated $5.24K.
  • Trevi Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2049 holding.
  • Los Angeles Capital Management first reported a position in Trevi Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Los Angeles Capital Management's Trevi Therapeutics position peaked at $89.6K in Q2 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.